The chemotherapy given before a stem cell transplant depends on whether you’re receiving your own cells back (autologous) or cells from a donor (allogeneic), and on the disease being treated. For autologous transplants, high-dose melphalan is the standard for multiple myeloma, while a four-drug combination called BEAM is most common for lymphoma. Allogeneic transplants typically use busulfan paired with either cyclophosphamide or fludarabine. This pre-transplant chemotherapy is called “conditioning,” and it serves a specific set of biological purposes.
Why Conditioning Chemotherapy Is Necessary
Conditioning isn’t just about killing cancer cells. It does three things at once. First, it depletes the stem cells already living in your bone marrow, clearing physical space for the new or reinfused cells to settle in. Second, it suppresses your immune system enough to prevent your body from rejecting the incoming stem cells. Third, in cancers of the blood and bone marrow, it works to wipe out as much remaining disease as possible.
A conditioning regimen targets two cell populations: the stem cells in your bone marrow (myelodepletion) and the immune cells in your lymphatic system (lymphodepletion). The balance between these two goals shifts depending on the type of transplant and the disease being treated.
Conditioning for Autologous Transplants
In an autologous transplant, you receive your own stem cells back after high-dose chemotherapy. Because there’s no donor mismatch, the conditioning doesn’t need to suppress your immune system as aggressively. The main goal is delivering the highest tolerable dose of chemotherapy to destroy cancer cells.
For multiple myeloma, the standard regimen is melphalan at 200 mg/m² of body surface area. This single-drug approach has been validated in the clinical trials that originally proved autologous transplant was superior to non-intensive chemotherapy for myeloma. Some patients who are older or have kidney problems or other health concerns receive a reduced dose of 140 mg/m², which is common in everyday clinical practice even though the full dose remains the benchmark.
For Hodgkin lymphoma and non-Hodgkin lymphoma, the most frequently used regimen is BEAM, a combination of four drugs: carmustine (BCNU), etoposide, cytarabine (Ara-C), and melphalan. BEAM is typically given over six days in the hospital and is used for several lymphoma subtypes, including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and Hodgkin lymphoma.
Conditioning for Allogeneic Transplants
Allogeneic transplants use cells from a matched donor, which means the conditioning regimen has a dual job: destroy disease and suppress the immune system enough to let donor cells engraft without being rejected. The drug combinations tend to be more complex.
The most established regimen pairs busulfan with cyclophosphamide. Busulfan is an alkylating agent that destroys bone marrow cells, while cyclophosphamide provides both anti-cancer and immune-suppressing effects. This combination has been a workhorse of allogeneic transplantation for decades.
A newer variation swaps cyclophosphamide for fludarabine. Fludarabine is a powerful immunosuppressant that also enhances the cancer-killing activity of busulfan by interfering with how cells repair their DNA. The busulfan-fludarabine combination generally causes fewer side effects, making it appealing for patients who might not tolerate the older regimen well. However, some studies in leukemia and myelodysplastic syndrome have found that overall and relapse-free survival may be slightly lower compared to busulfan-cyclophosphamide, so the choice involves tradeoffs.
Other allogeneic combinations include busulfan with thiotepa and cyclophosphamide, or busulfan with cyclophosphamide and etoposide. Some reduced-intensity protocols add antithymocyte globulin (ATG) to fludarabine and cyclophosphamide for additional immune suppression.
Full Intensity vs. Reduced Intensity
Conditioning regimens come in three intensity levels: myeloablative (full intensity), reduced-intensity, and nonmyeloablative (minimal intensity). The distinction matters because it determines who can safely undergo transplant.
Myeloablative conditioning delivers the highest doses and completely destroys the bone marrow. Without a stem cell infusion afterward, the marrow would not recover on its own. This approach gives the strongest anti-cancer effect but also causes the most toxicity.
Reduced-intensity and nonmyeloablative regimens use lower drug doses. They still suppress the immune system enough for donor cells to engraft, but they cause less organ damage. These protocols were developed specifically for patients over 65 to 70 and those with significant health problems like heart disease, lung disease, or prior organ damage from earlier cancer treatment. Before reduced-intensity conditioning existed, many of these patients were simply ineligible for transplant. Since most blood cancers are diagnosed in people between 65 and 70, this opened the door for a large group of patients.
When Radiation Replaces or Joins Chemo
Some conditioning regimens add total body irradiation (TBI) alongside chemotherapy, or use it as the primary conditioning tool. This is especially relevant in acute lymphoblastic leukemia (ALL). A large meta-analysis of over 5,600 pediatric and young adult ALL patients found that TBI-based regimens were associated with 21% better overall survival and a 31% lower risk of relapse compared to chemotherapy-only conditioning. Both approaches carried similar risks of graft-versus-host disease and treatment-related death, making TBI the preferred option for many ALL patients undergoing allogeneic transplant.
For patients in their first complete remission, however, the survival advantage of TBI over chemotherapy alone largely disappeared, suggesting that the benefit is most meaningful in higher-risk situations.
The Conditioning Timeline
Conditioning treatment typically lasts 1 to 9 days, depending on the regimen. The transplant day, when stem cells are infused, is designated “Day 0.” Everything before it counts backward: if your conditioning starts seven days before infusion, that’s Day -7. After the last dose of chemotherapy, you usually get a couple of rest days before the stem cell infusion to let the drugs clear your system.
If you’re staying in the hospital, you’ll generally be admitted a day or more before conditioning begins. For BEAM in lymphoma, the entire conditioning phase runs about six days, after which patients remain hospitalized until their blood counts recover and they’re clinically stable.
Side Effects During Conditioning
Conditioning chemotherapy is given at much higher doses than standard cancer treatment, which means the side effects are more intense. One of the most common is oral mucositis, painful inflammation and sores in the mouth and throat. About 76% of bone marrow transplant patients develop mucositis, compared to roughly 40% of patients on standard-dose chemotherapy. The sores can make eating, drinking, and swallowing difficult for days to weeks.
Because conditioning destroys the bone marrow, your white blood cell count drops to near zero, a state called neutropenia. During this period, which typically lasts until the new stem cells begin producing blood cells, you’re at high risk for infections. Bacteria and fungi that normally wouldn’t cause problems can become serious threats. This is the main reason transplant patients stay in filtered-air hospital rooms with strict infection precautions during the early recovery period.
Other common side effects include nausea, fatigue, hair loss, and diarrhea. The severity depends on the specific drugs used and their doses, which is one reason reduced-intensity regimens were developed as an alternative for patients less likely to tolerate full myeloablative conditioning.